R&D channel feed – Endpoints News

R&D channel feed

AbbVie and Harvard team up to find new drugs for the next new viruses

5 years ago

Cancer Research UK and NCI to kick off next rounds of Grand Challenges

5 years ago

Another biotech — Seattle-based Athira — files for an IPO, hoping to finally break through in Alzheimer's

5 years ago

Will supply chain demands freeze Pfizer and BioNTech out of a big chunk of the Covid-19 market?

5 years ago

That pipeline AbbVie acquired in the $63B Allergan buyout? It’s not doing so well

5 years ago

Cosmo spinout Cassiopea wins FDA approval for new acne drug

5 years ago

Triumvira snags $55M Series A to guide TAC technology to the clinic

5 years ago

Clene Nanomedicine, researching the use of gold atoms to slow ALS progression, nets $42.5M Series D

5 years ago

Moderna takes one more step along the high-wire act of Covid-19 vaccine work, offering markers of success for the most vulnerable age group

5 years ago

Vivek Ramaswamy’s Dermavant team looks to take on Amgen’s $13.4B psoriasis contender Otezla with a promising PhIII readout for a topical rival

5 years ago

Novartis finds a third-generation scion to an aging Gleevec, successfully taking on a Pfizer rival for last-chance CML patients

5 years ago

Agios just sold off the royalty rights for $255M, but Bristol Myers says Idhifa was a bust in PhIII. Now what?

5 years ago

Ovid gets quick raise off PhII seizure results. Can the results hold up against GW?

5 years ago

Takeda inks up to $500M collaboration with extra-cellular matrix biotech for NASH

5 years ago

Tricida 'foreshadowed' its CRL — but shares still fall with fear of years-long delay

5 years ago

Onconova reports PhIII flop, putting high-risk MDS program on the chopping block

5 years ago

Novartis’ PD-(L)1 catch-up attempt stumbles in PhIII

5 years ago

J&J adds yet another multiple myeloma regimen to the Darzalex label as Sanofi rival jumps in

5 years ago

Derailed gene therapy study reports 3rd death as safety and durability issues cloud a booming field

5 years ago

Novartis gets the green light to start marketing its next prospective blockbuster. And they're charging a premium for convenience

5 years ago

Watch out Bristol Myers, Merck is right on your heels with more positive Keytruda data to take to the FDA

5 years ago

Alzheon returns, with a $47M NIH grant and one last shot at a pivotal PhIII Alzheimer’s success

5 years ago

Regeneron flashes ‘great advance' in the NEJM for that other cholesterol drug sitting at the FDA

5 years ago

Turning Point touts positive pivotal NSCLC data, hints at even faster OK — but can it beat Pfizer and Roche?

5 years ago

First page Previous page 191 192 193194195 196 197 Next page Last page